Protective effect of endogenous PPARγ against acute gastric mucosal lesions associated with ischemia-reperfusion
Open Access
- 1 August 2004
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 287 (2) , G452-G458
- https://doi.org/10.1152/ajpgi.00523.2003
Abstract
Acute gastric mucosal lesions (AGMLs) are an important cause of gastrointestinal bleeding. Herein, we demonstrate that peroxisome proliferator-activated receptor-γ (PPARγ), a member of a nuclear receptor family, functions as an endogenous anti-inflammatory pathway in a murine model of AGML induced by ischemia-reperfusion (I/R). Treatment with specific PPARγ ligands such as BRL-49653, pioglitazone, or troglitazone was examined in a model of AGML induced by I/R. PPARγ-deficient and wild-type mice were also examined for their response to I/R in stomach. Specific PPARγ ligands exhibited dramatic and rapid protection against AGML formation associated with I/R in mice in a dose-dependent manner. In contrast, the AGML induced by I/R in PPARγ-deficient mice was more severe than that observed in wild-type mice. Administration of the PPARγ ligand significantly inhibited the upregulation of TNF-α, ICAM-1, inducible nitric oxide synthase, apoptosis, and nitrotyrosine formation induced by I/R in the stomach. These data indicate that an endogenous pathway associated with PPARγ plays an important role in the pathogenesis of I/R-associated injury in the stomach.Keywords
This publication has 25 references indexed in Scilit:
- A novel PPARγ gene therapy to control inflammation associated with inflammatory bowel disease in a murine modelGastroenterology, 2003
- Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitisGastroenterology, 2003
- PPARγ and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's diseaseTrends in Molecular Medicine, 2001
- Attenuation of Colon Inflammation through Activators of the Retinoid X Receptor (Rxr)/Peroxisome Proliferator–Activated Receptor γ (Pparγ) HeterodimerThe Journal of Experimental Medicine, 2001
- Insights into insulin resistance and type 2 diabetes from knockout mouse modelsJournal of Clinical Investigation, 2000
- A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory responseJournal of Clinical Investigation, 1999
- Mediators of inflammationCurrent Opinion in Immunology, 1997
- A new gastric ulcer model induced by ischemia-reperfusion in the rat: Role of leukocytes on ulceration in rat stomachLife Sciences, 1996
- 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγCell, 1995
- Upper GI Bleeding in an Urban HospitalAnnals of Surgery, 1990